Citations

Clear

3138 citation(s) found for "Smith, AM".

How can mate-pair sequencing be utilized for cancer patients?
Gao, Ge , Smith, David I, Smith, David I

Mayo Clinic

Expert Review of Molecular Diagnostics | November 10, 2016 | Volume: 17 | Issue: 1 | Pages: 1-3

10.1080/14737159.2017.1259569 | PMID 27830954 Get It

Assessment of Drug Sensitivity in Hematopoietic Stem and Progenitor Cells from Acute Myelogenous Leukemia and Myelodysplastic Syndrome Ex Vivo
Knorr, Katherine , Finn, Laura , Hess, Allan D., Foran, James M. , Karp, Judith E. , Knorr, Katherine L B, Finn, Laura E, Smith, B. Douglas , Kaufmann, Scott H.

Mayo Clinic

Stem Cells Translational Medicine | November 8, 2016 | Volume: 6 | Issue: 3 | Pages: 840-850

10.5966/sctm.2016-0034 | PMID 28297583 Get It

Abstract Current understanding suggests that malignant stem and progenitor cells must be reduced or eliminated for prolonged remissions in myeloid neoplasms such as acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS). Multicolor flow cytometry has been widely used to distinguish stem and myeloid progenitor cells from other populations in normal and malignant bone marrow. In this study, we present a method for assessing drug sensitivity in MDS and AML patient hematopoietic stem and myeloid progenitor cell populations ex vivo using the investigational Nedd8-activating enzyme inhibitor MLN4924 and standard-of-care agent cytarabine as examples. Utilizing a multicolor flow cytometry antibody panel for identification of hematopoietic stem cells, multipotent progenitors, common myeloid progenitors, granulocyte-monocyte progenitors, and megakaryocyte-erythroid progenitors present in mononuclear cell fractions isolated from bone marrow aspirates, we compare stem and progenitor cell counts after treatment for 24 hours with drug versus diluent. We demonstrate that MLN4924 exerts a cytotoxic effect on MDS and AML stem and progenitor cell populations, whereas cytarabine has more limited effects. Further application of this method for evaluating drug effects on these populations ex vivo and in vivo may inform rational design and selection of therapies in the clinical setting.
Diagnosis of Acute Cellular Rejection and Antibody-Mediated Rejection on Lung Transplant Biopsies: A Perspective From Members of the Pulmonary Pathology Society
Roden, Anja C. , Aisner, Dara L. , Allen, Timothy Craig, Aubry, Marie Christine, Barrios, Roberto, Beasley, Mary Beth , Cagle, Philip T., Capelozzi, Vera Luíza , Đačić, Sanja , Ge, Yimin , Lantuéjoul, Sylvie , Miller, Ross A., Moreira, André , Raparia, Kirtee, Sholl, Lynette M. , Tsao, Ming‐Sound , Vivero, Marina , Yatabe, Yasushi , Yi, Eunhee S. , Hariri, Lida P. , Miller, Ross, Mino-Kenudson, Mari A. , Rekhtman, Natasha , Smith, Maxwell L.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | November 7, 2016 | Volume: 141 | Issue: 3 | Pages: 437-444

10.5858/arpa.2016-0459-sa | PMID 27819763 Get It

Context.— The diagnosis and grading of acute cellular and antibody-mediated rejection (AMR) in lung allograft biopsies is important because rejection can lead to acute graft dysfunction and/or failure and may contribute to chronic graft failure. While acute cellular rejection is well defined histologically, no reproducible specific features of AMR are currently identified. Therefore, a combination of clinical features, serology, histopathology, and immunologic findings is suggested for the diagnosis of AMR. Objective.— To describe the perspective of members of the Pulmonary Pathology Society (PPS) on the workup of lung allograft transbronchial biopsy and the diagnosis of acute cellular rejection and AMR in lung transplant. Data Sources.— Reports by the International Society for Heart and Lung Transplantation (ISHLT), experience of members of PPS who routinely review lung allograft biopsies, and search of literature database (PubMed). Conclusions.— Acute cellular rejection should be assessed and graded according to the 2007 working formulation of the ISHLT. As currently no specific features are known for AMR in lung allografts, the triple test (clinical allograft dysfunction, donor-specific antibodies, pathologic findings) should be used for its diagnosis. C4d staining might be performed when morphologic, clinical, and/or serologic features suggestive of AMR are identified.
Hippocampal volumes predict risk of dementia with Lewy bodies in mild cognitive impairment
Kantarci, Kejal , Lesnick, Timothy G. , Ferman, Tanis J. , Przybelski, Scott A. , Kremers, Walter K. , Jack, Clifford R. , Petersen, Ronald C. , Lesnick, Timothy, Smith, Glenn E. , Boeve, Bradley F. , Knopman, David S. , Jack, Clifford R , Kantarci, Kejal , Ferman, Tanis J , Kremers, Walter K

Mayo Clinic

Neurology | November 2, 2016 | Volume: 87 | Issue: 22 | Pages: 2317-2323

10.1212/wnl.0000000000003371 | PMID 27807186 Get It

A phase IIa study of afuresertib, an oral pan‐AKT inhibitor, in patients with Langerhans cell histiocytosis
Arceci, R.J., Allen, Carl E. , Jacobsen, Eric D. , Whitlock, James A. , Vassallo, Robert , Morris, Shannon R., Portnoy, Alison, Reedy, Beth Ann, Smith, Deborah A. , Noble, Robert, Murnane, Amy A., Cornfeld, Mark, Heaney, Mark , McClain, Kenneth L. , Vaiselbuh, Sarah R., Dunkel, Ira J. , Rodríguez‐Galindo, Carlos , Vassallo, Robert , McClain, Kenneth L , Allen, Carl E

Mayo Clinic

Pediatric Blood & Cancer | November 2, 2016 | Volume: 64 | Issue: 5 | Pages: No page available

10.1002/pbc.26325 | PMID 27804235 Get It

AbstractBackgroundLangerhans cell histiocytosis (LCH) is a clonal neoplasm characterized by widely varied clinical presentations, including multisystem involvement and systemic inflammatory symptoms. The AKT pathway is relevant to survival and proliferation of dendritic cells, and is also often upregulated in hematopoietic malignancies. A clinical response in an adult patient with LCH participating in the first‐in‐human trial of afuresertib prompted this prospective trial.ProcedureThe population in the current study included treatment‐naïve (n = 7) and recurrent/refractory patients with LCH (n = 10), who received oral afuresertib (125 mg). The majority of patients were treated for > 24 weeks, with four patients receiving treatment for > 48 weeks.ResultsPharmacokinetic analysis showed similar exposures in previously reported patients with other hematologic malignancies. Primary drug‐related toxicities included Grade 1/2 nausea, diarrhea, dyspepsia, and vomiting. Grade 3 toxicities included fatigue, diarrhea, and pain (one of each). Another severe adverse event involved soft tissue necrosis. The overall response rate in evaluable subjects was 33% in treatment‐naïve patients and 28% in patients with recurrent/refractory disease, which did not meet the predefined Bayesian criteria for efficacy.ConclusionAfuresertib has clinical activity in some patients with newly diagnosed and advanced LCH.
Safety Studies for Use of Adipose Tissue-Derived Mesenchymal Stromal/Stem Cells in a Rabbit Model for Osteoarthritis to Support a Phase I Clinical Trial
Riester, Scott M. , Denbeigh, Janet M. , Yang, Lin , Jones, Dakota L. , Mooij, Tristan de, Lewallen, Eric A. , Nie, Hai , Paradise, Christopher R. , Radel, Darcie J., Dudakovic, Amel , Camilleri, Emily T. , Qu, Wenchun , Krych, Aaron J. , Frick, Matthew A., Im, Hee‐Jeong , Dietz, Allan B. , Smith, Jay , Wijnen, André J. van , Camilleri, Emily , Lin, Yang , de Mooij, Tristan, Larson, Dirk R. , van Wijnen, Andre J, van Wijnen, Andre J , Krych, Aaron J , Dietz, Allan B , van Wijnen, Andre J , Camilleri, Emily

Mayo Clinic

Stem Cells Translational Medicine | October 27, 2016 | Volume: 6 | Issue: 3 | Pages: 910-922

10.5966/sctm.2016-0097 | PMID 28297568 Get It

AbstractAdipose-derived mesenchymal stem cells (AMSCs) offer potential as a therapeutic option for clinical applications in musculoskeletal regenerative medicine because of their immunomodulatory functions and capacity for trilineage differentiation. In preparation for a phase I clinical trial using AMSCs to treat patients with osteoarthritis, we carried out preclinical studies to assess the safety of human AMSCs within the intra-articular joint space. Culture-expanded human AMSCs grown in human platelet-lysate were delivered via intra-articular injections into normal healthy rabbit knees and knees at risk for the development of osteoarthritis after bilateral medial anterior hemimeniscectomy. Treatment outcomes and safety were evaluated by assessing the general health, function, and behavior of the animals. Joint tissues were analyzed by x-ray, magnetic resonance imaging, and histopathology. Intra-articular AMSC therapy was well tolerated in this study. We did not observe adverse systemic reactions, nor did we find evidence of damage to intra-articular joint tissues. Thus, the data generated in this study show a favorable safety profile for AMSCs within the joint space in support of a phase I clinical trial evaluating the clinical utility of AMSCs to treat osteoarthritis.
Progression of Interstitial Fibrosis during the First Year after Deceased Donor Kidney Transplantation among Patients with and without Delayed Graft Function
Heilman, Raymond L. , Qaqish, Ibrahim , Khamash, Hasan , Singer, Andrew L., Reddy, Kunam S. , Smith, Maxwell L. , Smith, Byron H. , Kaplan, Bruce

Mayo Clinic

Clinical Journal of the American Society of Nephrology | October 24, 2016 | Volume: 11 | Issue: 12 | Pages: 2225-2232

10.2215/cjn.05060516 | PMID 27797897 Get It

Background and objectives Delayed graft function is a form of AKI resulting from ischemia-reperfusion injury. Our aim was to study the effect of delayed graft function on the progression of interstitial fibrosis after deceased donor kidney transplantation. Design, setting, participants, & measurements Our study is a retrospective study of all patients transplanted at our center between July of 2003 and September of 2014 using a kidney from a deceased donor. The primary outcome was the progression of interstitial fibrosis on serial protocol biopsies done during the first year post-transplant. We analyzed the distribution of the change in the Banff interstitial fibrosis (ci) score between the delayed graft function and nondelayed graft function groups for all of the paired biopsies done at time 0 and 12 months post-transplant ( Δ fibrosis). We also performed a linear mixed model analyzing the difference in the slopes for the progression of mean Banff ci score for all of the biopsies done at time 0 and 1, 4, and 12 months post-transplant. Results There were 343 (36.7%) in the delayed graft function group and 591 in the control group. The biopsy rates for the delayed graft function and nondelayed graft function groups at time 0 were 65.3% ( n =224) and 67.0% ( n =396), respectively, and at 12 months, they were 64.4% ( n =221) and 68.4% ( n =404), respectively. Paired biopsies were available for 155 in the delayed graft function group and 283 in the control group. In a risk-adjusted model, Banff ci score >0 on the time 0 biopsy had a higher odds of delayed graft function (odds ratio, 1.70; 95% confidence interval, 1.03 to 2.82). The distribution of the Δ fibrosis between 0 and 12 months was similar in delayed graft function and control groups ( P =0.91). The slopes representing the progression of fibrosis were also similar between the groups ( P =0.66). Conclusions Donor-derived fibrosis may increase the odds of delayed graft function; however, delayed graft function does not seem to increase the progression of fibrosis during the first year after transplantation.
Update on Gender Equity in Immunology, 2001 to 2016
Kovats, Susan , Parent, Michelle A., Gaffen, Sarah L. , Hedrick, Catherine C. , Denzin, Lisa , Raghavan, Malini , Stephens, Robin , Shapiro, Virginia Smith , Kovats, Susan , Raghavan, Malini , Jain, Pooja

Mayo Clinic

The Journal of Immunology | October 18, 2016 | Volume: 197 | Issue: 10 | Pages: 3751-3753

10.4049/jimmunol.1601644 | PMID 27798172 Get It

Abstract In 2001, The American Association of Immunologists Committee on the Status of Women conducted a survey examining the percentage of women faculty members within immunology departments or women in immunology graduate programs across 27 institutions in the United States, comparing it to the percentage of women receiving a Ph.D. Here, we examine the representation of women across these same 27 immunology departments and programs to examine changes in gender equity over the last 15 years.